UK Government Seeks Pharmaceutical Sector's Views on Regulation Enforcement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

UK Government Seeks Pharmaceutical Sector's Views on Regulation Enforcement


The UK Department for Business Innovation & Skills is conducting a review of how well national regulators and local authorities enforce rules governing the pharmaceutical sector, and the group is seeking input from pharmaceutical producers, the department announced in a press release. The Focus on Enforcement review will be open for comment on the website and via email until September 2, 2013. The reviewers will also speak with individual businesses, trade bodies, and regulators. A response from regulators will follow the evidence-gathering phase of the review.

Ministers want to hear about any unnecessary burdens that are being placed on businesses and any duplication or inconsistencies between regulatory bodies. The review also seeks to find out whether companies are receiving the clear guidance they need to comply with the law. Firms are also invited to identify areas of good enforcement practice which could be replicated elsewhere.

“The UK pharmaceutical industry is a vital player in an increasingly competitive international market.  We must maximize its potential to attract investment, innovate, and create jobs, while maintaining world-class quality and safety standards,” said business minister Michael Fallon in the press release. “I want firms to tell us how we can improve the environment in which they work.  We want to make sure regulation is proportionately and intelligently applied to facilitate their contribution to our economy.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here